Literature DB >> 10223948

Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.

K L Oakley1, C B Moore, D W Denning.   

Abstract

We compared the in vitro activity of liposomal nystatin (Nyotran) with those of other antifungal agents against 60 Aspergillus isolates. Twelve isolates were itraconazole resistant. For all isolates, geometric mean (GM) MICs (micrograms per milliliter) were 2.30 for liposomal nystatin, 0.58 for itraconazole, 0.86 for amphotericin B (AB) deoxycholate, 9.51 for nystatin, 2.07 for liposomal AB, 2.57 for AB lipid complex, and 0.86 for AB colloidal dispersion. Aspergillus terreus (GM, 8.72 micrograms/ml; range, 8 to 16 micrograms/ml) was significantly less susceptible to all of the polyene drugs than all other species (P = 0.0001).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223948      PMCID: PMC89255     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Fungicidin, an antibiotic produced by a soil actinomycete.

Authors:  E L HAZEN; R BROWN
Journal:  Proc Soc Exp Biol Med       Date:  1951-01

2.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Lipid complexes of amphotericin B: the competitive picture.

Authors:  M D Richardson
Journal:  J Med Microbiol       Date:  1997-03       Impact factor: 2.472

4.  Some effects of nystatin on the growth of four Aspergillus species.

Authors:  V C Stanley; M P English
Journal:  J Gen Microbiol       Date:  1965-07

5.  Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.

Authors:  T L Wallace; V Paetznick; P A Cossum; G Lopez-Berestein; J H Rex; E Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

6.  Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Authors:  E M Johnson; J O Ojwang; A Szekely; T L Wallace; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965

8.  Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.

Authors:  R T Mehta; R L Hopfer; L A Gunner; R L Juliano; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 9.  Overview of amphotericin B colloidal dispersion (amphocil).

Authors:  D A Stevens
Journal:  J Infect       Date:  1994-05       Impact factor: 6.072

Review 10.  Liposomal amphotericin B, AmBisome.

Authors:  R J Hay
Journal:  J Infect       Date:  1994-05       Impact factor: 6.072

View more
  13 in total

1.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 2.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.

Authors:  J Mosquera; P A Warn; J Morrissey; C B Moore; C Gil-Lamaignere; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.

Authors:  D W Denning; P Warn
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Differential antifungal activity of isomeric forms of nystatin.

Authors:  L Ostrosky-Zeichner; S Bazemore; V L Paetznick; J R Rodriguez; E Chen; T Wallace; P Cossum; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Identification of Aspergillus fumigatus and related species by nested PCR targeting ribosomal DNA internal transcribed spacer regions.

Authors:  J Zhao; F Kong; R Li; X Wang; Z Wan; D Wang
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

8.  Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

Authors:  Fritz Offner; Vladimir Krcmery; Marc Boogaerts; Chantal Doyen; Dan Engelhard; Patricia Ribaud; Catherine Cordonnier; Ben de Pauw; Simon Durrant; Jean-Pierre Marie; Philippe Moreau; Harry Guiot; George Samonis; Richard Sylvester; Raoul Herbrecht
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.

Authors:  Matthias Brock; Grégory Jouvion; Sabrina Droin-Bergère; Olivier Dussurget; Marie-Anne Nicola; Oumaïma Ibrahim-Granet
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

10.  Nystatin-intralipid preparation: characterization and in vitro activity against yeasts and molds.

Authors:  R Semis; I Polacheck; E Segal
Journal:  Mycopathologia       Date:  2010-01-13       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.